CTOR - Citius Oncology, Inc. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

CTOR

CITIUS ONCOLOGY, INC.

NASDAQ

$0.78

▼ DOWN 1.86% (-0.01)

KEY STATISTICS

Market Cap$72.12 M

52w High$2.25

52w Low$0.49

Dividend Yield—

Frequency—

P/E-1.65

Volume21.70K

Shares Out.92.98M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Leonard L. Mazur

ABOUT

SECTOR

Healthcare

WENT PUBLIC

December 8, 2022

METHOD OF GOING PUBLIC

N/A

FULL TIME EMPLOYEES

285

PRICE TARGET

Target High$6.00

Target Low$6.00

Target Median$6.00

Target Consensus$6.00

UPCOMING EARNINGS

DateDec 17, 2026

DayThursday

Rev. Est.$5.77M

DEC

THU

PRICE

$0.78 ▼ DOWN 1.86% (−$0.01)

About Citius Oncology, Inc.

https://www.citiusonc.com/overview/default.aspx ↗

Citius Oncology, Inc., based in New York, develops targeted cancer therapies, including LYMPHIR for relapsed/refractory cutaneous T-cell lymphoma, and operates as a subsidiary of Citius Pharmaceuticals.

INDUSTRY

Medical - Pharmaceuticals

A PRODUCT CITIUS ONCOLOGY, INC. IS KNOWN FOR

LYMPHIR™ (denileukin diftitox-cxdl)

LYMPHIR, FDA-approved for relapsed/refractory CTCL, is Citius Oncology's first commercial product, marking its shift to a commercial-stage oncology company focused on U.S. and international market expansion.